Pacing and clinical electrophysiology : PACE · 2026
Comparative Outcomes of Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients With Lower Stroke Risk.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Amanda, Khan Muhammad Zia, Alruwaili Waleed, Khan Muhammad Usman, Bilal Muhammad, Zahid Salman, Gonuguntla Karthik, Khan Samrina, Mendez Melody, Asad Zain Ul Abideen, Agarwal Siddharth, Balla Sudarshan, Darden Douglas, Munir Muhammad Bilal
Аннотация
BACKGROUND: Current guidelines recommend oral anticoagulation in atrial fibrillation (AF) patients with a CHA2DS2-VASc score ≥2 for stroke prevention. However, Centers for Medicare & Medicaid Services (CMS) reimburses left atrial appendage occlusion (LAAO) for patients with CHA2DS2-VASc score ≥3. This study aimed to evaluate differences in outcomes and complications of LAAO therapy in AF patients with a CHA2DS2-VASc score of ≥ 3 versus < 3.
METHODS: National Inpatient Sample (NIS) and International Classification of Diseases, Tenth Revision codes were used to identify LAAO device implantation in the U.S. from years 2016 to 2020. The study population was stratified by stroke risk into two groups, CHA2DS2-VASc ≥ 3 and < 3. Study endpoints assessed included procedural complications, inpatient outcomes and resource utilization.
RESULTS: A total of 73,795 and 15,500 LAAO devices were implanted in patients with CHA2DS2-VASc ≥ 3 and < 3, respectively. Compared to patients with CHA2DS2-VASc score of ≥ 3, patients with CHA2DS2-VASc < 3 had lower overall (6.9% vs 9.9%, P < 0.01) and major (4.5% vs 6.2%, P < 0.01) complications in the crude analysis. After multivariable adjustment for potential confounders, CHA2DS2-VASc < 3 was associated with lower overall complications (aOR 0.84, 95% CI 0.78 - 0.91), major complications (aOR 0.90, 95% CI 0.81-0.99) and cost of hospitalization (aOR 0.95, 95% CI 0.91-0.99).
CONCLUSIONS: Patients with CHA2DS2-VASc < 3 had lower complications and hospitalization costs after LAAO device implantation. These data, if redemonstrated in a large randomized trial, can have important clinical implications for stroke prevention in AF patients.
METHODS: National Inpatient Sample (NIS) and International Classification of Diseases, Tenth Revision codes were used to identify LAAO device implantation in the U.S. from years 2016 to 2020. The study population was stratified by stroke risk into two groups, CHA2DS2-VASc ≥ 3 and < 3. Study endpoints assessed included procedural complications, inpatient outcomes and resource utilization.
RESULTS: A total of 73,795 and 15,500 LAAO devices were implanted in patients with CHA2DS2-VASc ≥ 3 and < 3, respectively. Compared to patients with CHA2DS2-VASc score of ≥ 3, patients with CHA2DS2-VASc < 3 had lower overall (6.9% vs 9.9%, P < 0.01) and major (4.5% vs 6.2%, P < 0.01) complications in the crude analysis. After multivariable adjustment for potential confounders, CHA2DS2-VASc < 3 was associated with lower overall complications (aOR 0.84, 95% CI 0.78 - 0.91), major complications (aOR 0.90, 95% CI 0.81-0.99) and cost of hospitalization (aOR 0.95, 95% CI 0.91-0.99).
CONCLUSIONS: Patients with CHA2DS2-VASc < 3 had lower complications and hospitalization costs after LAAO device implantation. These data, if redemonstrated in a large randomized trial, can have important clinical implications for stroke prevention in AF patients.